The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the company a successor to its blockbuster therapy Ofev. Phosphodiesterase (PDE ...
Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...